Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia

Objectives To assess the relevance of vancomycin-intermediate susceptibility (VISA) and heteroresistance (hVISA) in methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. Methods We determined vancomycin MICs for 371 saved MRSA blood isolates (2002-03; 2005-06) by Etest and broth microdilut...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2011-07, Vol.66 (7), p.1594-1599
Hauptverfasser:	Khatib, Riad, Jose, Jinson, Musta, Adina, Sharma, Mamta, Fakih, Mohamad G., Johnson, Leonard B., Riederer, Kathleen, Shemes, Stephen
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Bacteremia - drug therapy Bacteremia - microbiology Bacterial diseases Bacterial sepsis Biological and medical sciences Chemotherapy Female Genotype & phenotype Human bacterial diseases Humans Infectious diseases Male Medical sciences Methicillin-Resistant Staphylococcus aureus - drug effects Methicillin-Resistant Staphylococcus aureus - isolation & purification Microbial Sensitivity Tests Middle Aged Pharmacology. Drug treatments Staphylococcal Infections - drug therapy Staphylococcal Infections - microbiology Staphylococcal infections, streptococcal infections, pneumococcal infections Staphylococcus aureus Staphylococcus infections Treatment Outcome Vancomycin - pharmacology Vancomycin - therapeutic use Vancomycin Resistance
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives To assess the relevance of vancomycin-intermediate susceptibility (VISA) and heteroresistance (hVISA) in methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. Methods We determined vancomycin MICs for 371 saved MRSA blood isolates (2002-03; 2005-06) by Etest and broth microdilution (BMD), screened for hVISA (Etest methods), determined the population analysis profile (PAP)/AUC for isolates with suspected reduced susceptibility (MICs >2 mg/L and/or hVISA-screen-positive versus Mu3 (hVISA control), and stratified patient characteristics and outcome according to susceptibility phenotype: VISA (PAP/AUC >1.3), hVISA (PAP/AUC 0.9-1.3), and susceptible (S-MRSA; PAP/AUC
ISSN:	0305-7453 1460-2091
DOI:	10.1093/jac/dkr169